Vanda Pharmaceuticals (FRA:VM4) Valuation Rank


FRA:VM4 Vanda Pharmaceuticals Inc FRA:VM4
75 GF Score
Price €5.10
GF Value €4.70
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Vanda Pharmaceuticals Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Vanda Pharmaceuticals Valuation Rank Related Terms

FRA:VM4
75GF Score
Vanda Pharmaceuticals Inc FRA:VM4
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Vanda Pharmaceuticals (FRA:VM4) Overvalued in 2026?

Based on GuruFocus' analysis, Vanda Pharmaceuticals stock appears to be overvalued. The current stock price of €5.10 is trading 8.5% above its estimated GF Value™ of €4.70. GuruFocus considers Vanda Pharmaceuticals to be Fairly Valued.

Key valuation signals for FRA:VM4:

  • Valuation Rank:
  • GF Value™: €4.70 vs. price of €5.10 (8.5% above fair value)
  • GF Score™: 75/100 with 4 warning signs

No single metric tells the full story. See the FRA:VM4 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vanda Pharmaceuticals Business Description

Other Exchanges VNDA:USA0LKB:UKVM4:Germany
Address 2200 Pennsylvania Avenue North West, Suite 300 E, Washington, DC, USA, 20037
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
75GF Score

Get the complete analysis for FRA:VM4

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.10
Price
€4.70
GF Value